Tramadal Hydrochloride and Acetaminophen description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Tramadal Hydrochloride and Acetaminophen

REMEDYREPACK INC.


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

TRAMADAL HYDROCHLORIDE AND ACETAMINOPHEN DESCRIPTION



Tramadal Hydrochloride and Acetaminophen



Tramadal Hydrochloride and Acetaminophen




CLINICAL PHARMACOLOGY

The following information is based on studies of tramadol alone or acetaminophen alone, except where otherwise noted:

PHARMACODYNAMICS

Tramadol

CLINICAL PHARMACOLOGY: Pharmacokinetics



Acetaminophen


PHARMACOKINETICS




**

Absorption



Food Effects


Distribution



Metabolism
PRECAUTIONS: Drug Interactions
WARNINGS

  • ●     conjugation with sulfate; and
  • ●     oxidation via the cytochrome, P450-dependent, mixed-function oxidase enzyme pathway to form a reactive intermediate metabolite, which conjugates with glutathione and is then further metabolized to form cysteine and mercapturic acid conjugates. The principal cytochrome P450 isoenzyme involved appears to be CYP2E1, with CYP1A2 and CYP3A4 as additional pathways.


Elimination



USE IN SPECIFIC POPULATIONS

Renal
DOSAGE AND ADMINISTRATION

Hepatic
PRECAUTIONSDOSAGE AND ADMINISTRATION

Geriatric
PRECAUTIONS: Geriatric Use

Gender


Pediatric


CLINICAL STUDIES

Single Dose Studies for Treatment of Acute Pain


INDICATIONS & USAGE



TRAMADAL HYDROCHLORIDE AND ACETAMINOPHEN CONTRAINDICATIONS



WARNINGS

Seizure Risk

  •      Selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics),
  • ●     Tricyclic antidepressants (TCAs), and other tricyclic compounds (e.g., cyclobenzaprine, promethazine, etc.), or
  • ●     Other opioids.
Administration of tramadol may enhance the seizure risk in patients taking:
  •      MAO inhibitors (see alsoWARNINGS: Use with MAO Inhibitors),
  • ●     Neuroleptics, or
  • ●     Other drugs that reduce the seizure threshold.


Anaphylactoid Reactions
CONTRAINDICATIONS

Respiratory Depression
WARNINGS: Seizure RiskOVERDOSAGE

Interaction With Central Nervous System (CNS) Depressants


Increased Intracranial Pressure or Head Trauma
Respiratory Depression

Use in Ambulatory Patients


Use With MAO Inhibitors and Serotonin Reuptake Inhibitors


Use With Alcohol


Use With Other Acetaminophen-containing Products


Withdrawal
DRUG ABUSE AND DEPENDENCE

Physical Dependence and Abuse
DRUG ABUSE AND DEPENDENCE

Risk of Overdosage
OVERDOSAGE


PRECAUTIONS

General

WARNINGS: Use With Other Acetaminophen-containing ProductsRisk of Overdosage

PEDIATRIC USE



GERIATRIC USE


Acute Abdominal Conditions


Use in Renal Disease


Use in Hepatic Disease
WARNINGS: Use With Alcohol

INFORMATION FOR PATIENTS

  • ●Tramadol hydrochloride and acetaminophen tablets may impair mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
  • ●Tramadol hydrochloride and acetaminophen tablets should not be taken with alcohol-containing beverages.
  • ●The patient should be instructed not to take tramadol hydrochloride and acetaminophen tablets in combination with other tramadol or acetaminophen-containing products, including over-the-counter preparations.
  • ●Tramadol hydrochloride and acetaminophen tablets should be used with caution when taking medications such as tranquilizers, hypnotics or other opiate containing analgesics.
  • ●The patient should be instructed to inform the physician if they are pregnant, think they might become pregnant, or are trying to become pregnant (seePRECAUTIONS: Labor and Delivery).
  • ●The patient should understand the single-dose and 24-hour dose limit and the time interval between doses, since exceeding these recommendations can result in respiratory depression, seizures, hepatic toxicity and death.

DRUG INTERACTIONS



Use With Carbamazepine


Use With Quinidine


Use With Inhibitors of CYP2D6


Use With Cimetidine


Use With MAO Inhibitors
WARNINGS: Use With MAO Inhibitors

Use With Digoxin


Use With Warfarin Like Compounds



CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY






PREGNANCY

Teratogenic Effects

Pregnancy Category C


Nonteratogenic Effects


LABOR & DELIVERY

DRUG ABUSE AND DEPENDENCE


NURSING MOTHERS




TRAMADAL HYDROCHLORIDE AND ACETAMINOPHEN ADVERSE REACTIONS




**
Incidence At Least 1%, Causal Relationship At Least Possible Or Greater

Body as a Whole:
Central and Peripheral Nervous System:
Gastrointestinal System:
Psychiatric Disorders:
Skin and Appendages:

Selected Adverse Events Occurring At Less Than 1%

Body as a Whole:
Cardiovascular Disorders
Central and Peripheral Nervous System:
Gastrointestinal System:
Hearing and Vestibular Disorders:
Heart Rate and Rhythm Disorders:
Liver and Biliary System:
Metabolic and Nutritional Disorders:
Psychiatric Disorders:
Red Blood Cell Disorders:
Respiratory System:
Urinary System:
Vision Disorders:

Other Clinically Significant Adverse Experiences Previously Reported With Tramadol Hydrochloride



Other Clinically Significant Adverse Experiences Previously Reported With Acetaminophen


DRUG ABUSE AND DEPENDENCE

WARNINGS

OVERDOSAGE



Tramadol
WARNINGS

Acetaminophen


Treatment of Overdose




DOSAGE & ADMINISTRATION



Individualization of Dose


HOW SUPPLIED







STORAGE AND HANDLING




PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION














Tramadal Hydrochloride and Acetaminophen

Tramadal Hydrochloride and Acetaminophen

Tramadal Hydrochloride and Acetaminophen

Tramadal Hydrochloride and Acetaminophen TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:49349-791(NDC:0378-8088)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
TRAMADOL HYDROCHLORIDE TRAMADOL 37.5 mg
ACETAMINOPHEN ACETAMINOPHEN 325 mg

Inactive Ingredients

Ingredient Name Strength
SILICON DIOXIDE
CROSPOVIDONE
HYPROMELLOSES
lactose monohydrate
MAGNESIUM STEARATE
polyethylene glycol
povidone
STARCH, CORN
STEARIC ACID
titanium dioxide
triacetin
FERRIC OXIDE YELLOW

Product Characteristics

Color Size Imprint Code Shape
yellow 11 mm P;T;M ROUND

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:49349-791-03 20 in 1 BLISTER PACK

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA077858 2011-10-17


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.